Acorda Therapeutics is a biopharmaceutical company that specializes in the development and commercialization of therapies for central nervous system (CNS) disorders. The company has a wide range of products and is dedicated to making a difference in the lives of people who have CNS disorders. Uses: One of the most popular products of Acorda Therapeutics is Ampyra (dalfampridine). It is indicated for the improvement of walking in adult patients with multiple sclerosis (MS), which is a chronic, autoimmune, inflammatory disease that affects the CNS. It is also the only FDA approved drug that improves walking in MS patients. Dosage: Ampyra is available in 10mg tablets that are to be taken orally. The recommended dosage is one tablet twice a day, with a gap of roughly 12 hours between the doses. It is important to note that this medication should not be taken in combination with other medications that contain dalfampridine, as it can lead to an overdose. Side effects: As with any medication, Ampyra has its potential side effects. Some of the most common side effects that have been reported are urinary tract infection, insomnia, dizziness, headache, nausea, back pain, tremors, and allergic reaction. If any of these side effects persist or worsen, it is important to consult a doctor. Interactions: There are currently no known drug interactions for Ampyra. However, it is important to inform your doctor if you are taking any other medications or supplements as they may have an impact on the efficacy of this medication. Generic: There is currently no generic version of Ampyra available in the market as it is a patented drug exclusively owned by Acorda Therapeutics. It is important to note that any medication marketed as a generic version of Ampyra is most likely counterfeit and may be harmful to your health. Demographic: As mentioned earlier, Ampyra is indicated for the improvement of walking in adult patients with multiple sclerosis who have already received other forms of therapy but have not experienced satisfactory improvement. According to the National Multiple Sclerosis Society, it is estimated that there are over 2.3 million people worldwide living with MS. In conclusion, Acorda Therapeutics is a leading biopharmaceutical company that is dedicated to improving patient outcomes for those who have CNS disorders. Ampyra is a popular product of Acorda Therapeutics and is indicated for the improvement of walking in adult patients with multiple sclerosis. The recommended dosage for Ampyra is one tablet twice a day, and it may cause several side effects such as urinary tract infection, insomnia, dizziness, headache, and allergic reactions. It is important to note that there are no known drug interactions for Ampyra, and that there is no generic version of this medication available in the market. Finally, the demographic for Ampyra is adult patients with MS who have already received other therapy but have not seen satisfactory improvement.